Daily Sepsis Research Analysis
Three studies advanced sepsis care from complementary angles: a large multicenter pediatric QI cohort linked neighborhood opportunity to disparities in sepsis recognition and showed improvement with standardization; a prospective registry analysis found earlier polymyxin B hemoperfusion in severe septic shock improved early hemodynamics and care-free days; and a double-blind RCT showed saffron reduced inflammatory markers and severity scores without mortality benefit.
Summary
Three studies advanced sepsis care from complementary angles: a large multicenter pediatric QI cohort linked neighborhood opportunity to disparities in sepsis recognition and showed improvement with standardization; a prospective registry analysis found earlier polymyxin B hemoperfusion in severe septic shock improved early hemodynamics and care-free days; and a double-blind RCT showed saffron reduced inflammatory markers and severity scores without mortality benefit.
Research Themes
- Health equity and standardization in pediatric sepsis care
- Timing of extracorporeal endotoxin adsorption in septic shock
- Adjunctive anti-inflammatory nutraceuticals in sepsis
Selected Articles
1. Association between Child Opportunity Index and paediatric sepsis recognition and treatment in a large quality improvement collaborative: a retrospective cohort study.
In a 24-hospital, 31,260-case retrospective cohort from the IPSO collaborative, children from neighborhoods with higher Child Opportunity Index were most likely to receive standardized sepsis recognition and care bundles. Over time, standardized recognition improved across all quintiles, with the largest gains among inpatients from the lowest COI neighborhoods, suggesting QI standardization can reduce care disparities.
Impact: Links neighborhood-level opportunity to pediatric sepsis care processes at scale and demonstrates that QI standardization can narrow disparities over time.
Clinical Implications: Health systems should implement standardized sepsis recognition and bundled care pathways across pediatric settings and target additional support to low-opportunity neighborhoods to reduce disparities.
Key Findings
- Among 31,260 pediatric sepsis cases from 24 hospitals, Very High COI patients had the highest standardized recognition (67.7%) and bundle delivery (46%).
- Standardized sepsis recognition improved over time across all COI quintiles, with the greatest gains among inpatients in the Very Low COI quintile.
- Quality improvement efforts focusing on standardization and shared learning were associated with narrowing disparities in sepsis care delivery.
Methodological Strengths
- Large multicenter cohort probabilistically linked to administrative/clinical data (PHIS) with standardized process measures.
- Temporal analysis using generalized linear models to assess changes over time across COI strata.
Limitations
- Observational retrospective design with potential residual confounding and selection biases.
- Mortality and timeliness outcomes may be influenced by unmeasured hospital- and patient-level factors; generalizability limited to participating centers.
Future Directions: Prospective QI trials targeting low-COI populations, evaluation of implementation strategies that sustain improvements, and linkage to patient-centered outcomes.
BACKGROUND: The Child Opportunity Index (COI) is a multidimensional measure of US neighbourhood-level conditions needed for healthy development. COI is associated with healthcare delivery and outcomes. Formal quality improvement (QI) may influence the relationship between COI, quality of care and outcomes in children. OBJECTIVE: To assess the association between COI and paediatric sepsis care delivery and outcomes and determine if baseline disparities in care change over time among hospitals in the Improving Pediatric Sepsis Outcomes (IPSO) collaborative. METHODS: Retrospective cohort study of IPSO patients probabilistically linked to the Pediatric Health Information System database from 2017 to 2021. Primary exposure was COI. We estimated differences in the proportions of patients in each COI quintile identified via standardised sepsis recognition protocols (screening tool, huddle documentation and/or order set use) and who received a bundle of recommended care (standardised sepsis recognition, plus bolus <1 hour and antibiotic <3 hours). We further assessed the timeliness of each bundle component and mortality. We evaluated changes in standardised sepsis recognition over time using generalised linear models. RESULTS: 31 260 sepsis cases from 24 hospitals were included. Cross-sectional analysis over the entire study period found patients in the Very High COI quintile were most likely to be identified via standardised recognition protocols and receive IPSO's recommended care bundle (67.7% and 46%, respectively). Over time, standardised sepsis recognition improved for all; the greatest improvements were among inpatients in the Very Low COI quintile. CONCLUSION: Disparities exist in paediatric sepsis care delivery by COI. Over the course of the IPSO collaborative, care improved most for children in the lowest COI quintile. QI collaboratives focused on standardisation and shared learning may reduce disparities.
2. Time to administer polymyxin B hemoperfusion and hemodynamics in patients with septic shock requiring high-dose norepinephrine: a predetermined analysis of a prospective cohort study.
In a predetermined analysis of 82 PMX-HP–treated septic shock patients from a prospective registry, earlier administration (relative to ICU admission) was associated with higher MAP at 6–8 hours, lower VIS from 8 hours onward, more vasopressor/inotrope-free days, and more ICU-free days. Ninety-day mortality trended lower (adjusted HR 0.38; 95% CI 0.13–1.09) but was not statistically significant.
Impact: Provides time-sensitive, real-world evidence that earlier PMX-HP may improve short-term hemodynamics and clinical course in severe septic shock.
Clinical Implications: For septic shock patients requiring high-dose norepinephrine, consider earlier PMX-HP initiation when indicated, while recognizing the need for randomized trials to confirm mortality effects.
Key Findings
- Median time from ICU admission to PMX-HP was 265 minutes; earlier administration improved MAP at 6–8 hours and reduced VIS from 8 hours onward.
- Early PMX-HP was associated with more vasopressor/inotrope-free days (23 vs 21; P=0.027) and ICU-free days (18 vs 14; P=0.025) within 28 days.
- Ninety-day mortality was lower in the early group (15.3% vs 31.3%; adjusted HR 0.38; 95% CI 0.13–1.09), though not statistically significant.
Methodological Strengths
- Prospective registry with predetermined analysis and objective hemodynamic endpoints (MAP, VIS) within 48 hours.
- Clinically meaningful secondary outcomes (vasopressor/inotrope-free and ICU-free days) and 90-day mortality assessment.
Limitations
- Non-randomized observational design with potential residual confounding and selection bias.
- Relatively small PMX-HP sample (n=82) and grouping by median time may not reflect optimal timing thresholds.
Future Directions: Randomized trials to test early PMX-HP initiation strategies, and biomarker- or phenotype-guided timing to optimize patient selection.
BACKGROUND: Delayed administration of polymyxin B hemoperfusion (PMX-HP) for septic shock could diminish its efficacy in real-world clinical settings. METHODS: BEAT-SHOCK (BEst Available Treatment for septic SHOCK) registry is a prospective registry consisting of 309 adult patients with septic shock requiring high-dose norepinephrine (≥ 0.2 μg/kg/min). This predetermined analysis included 82 patients treated with PMX-HP. They were grouped according to the median time from intensive care unit (ICU) admission to administration of PMX-HP: the early administration group (n = 40) and the late administration group (n = 42). The primary outcome was short-term hemodynamic status, including mean arterial pressure and vasoactive-inotropic score (VIS; calculated from doses of dopamine, dobutamine, norepinephrine, epinephrine, vasopressin, milrinone, and levosimendan) within 48 h after ICU admission. RESULTS: The median time from ICU admission to administration of PMX-HP was 265 min (interquartile range [IQR]: 113-480). The median ages were 70 (IQR: 59-81) and 72 (IQR: 64-80) years (P = 0.77), and 21/40 (53%) and 25/42 (60%) patients were male (P = 0.52) in the early and late administration groups, respectively. The dose of norepinephrine at ICU admission was 0.33 (IQR: 0.24-0.47) and 0.30 (IQR: 0.22-0.34) μg/kg/min in the early and late administration groups, respectively (P = 0.17). Within 48 h after ICU admission, mean arterial pressure was significantly higher at 6 h and 8 h, and VIS was significantly lower at 8 h and thereafter in the early administration group. Within a 28-day period, there were 23 (IQR: 21-25) and 21 (IQR: 0-24) vasopressor/inotrope-free days (P = 0.027), and 18 (IQR: 1-23) and 14 (IQR: 0-19) ICU-free days (P = 0.025) in the early and late administration groups, respectively. The cumulative mortality at 90 days was 15.3% in the early administration group and 31.3% in the late administration group (adjusted hazard ratio 0.38; 95% confidence interval 0.13-1.09). CONCLUSIONS: In patients with septic shock, early administration of PMX-HP was associated with higher mean arterial pressure and lower VIS within 48 h after ICU admission. Additionally, it may be associated with an improved clinical course, represented by more ICU-free and vasopressor/inotrope-free days. Trial registration UMIN Clinical Trial Registry on 1 November 2019 (registration no. UMIN000038302).
3. The effects of saffron supplementation on inflammation and hematological parameters in patients with sepsis: a randomized controlled trial.
In a double-blind RCT of 90 ICU sepsis patients, 7 days of saffron (100 mg/day) significantly reduced CRP, ESR, IL-6, IL-18, and TNF-α and improved APACHE II, SOFA, NUTRIC, and WBC counts versus placebo. No differences were observed in GCS, FOUR scores, or 28- and 90-day mortality, indicating biomarker and severity score improvements without demonstrated survival benefit.
Impact: First randomized double-blind trial to test a nutraceutical adjunct in sepsis demonstrating meaningful anti-inflammatory effects and improvements in severity scores.
Clinical Implications: Saffron shows promise as an adjunct to modulate inflammation in sepsis, warranting larger multicenter RCTs powered for clinical endpoints before adoption.
Key Findings
- Saffron significantly reduced inflammatory markers: CRP, ESR, IL-6, IL-18, and TNF-α (all P<0.001 vs placebo).
- Clinical severity indices improved: APACHE II (Δ -2.55 vs +0.78; P=0.003), SOFA (Δ -1.00 vs -0.05; P<0.001), NUTRIC (Δ -1.2 vs +0.2; P<0.001), and WBC count (Δ -4176 vs +62; P<0.001).
- No significant differences were observed in GCS, FOUR, or 28- and 90-day mortality or other hematologic parameters.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with trial registration.
- Comprehensive assessment of inflammatory biomarkers and validated severity scores.
Limitations
- Single-center, small sample size and short (7-day) intervention; not powered for mortality.
- Surrogate endpoints improved without corresponding survival benefit; external validity uncertain.
Future Directions: Multicenter, adequately powered RCTs to test dose, duration, and clinical endpoints (organ failure-free days, mortality), with pharmacokinetic and safety profiling.
BACKGROUND: Critically ill patients suffering from sepsis are at an increased risk of morbidity and mortality due to its serious complications. Saffron as an herbal medicine has been proven to have anti-inflammatory and anti-oxidative stress effects previously. Hence, this study aimed to determine how saffron supplementation affected inflammatory and hematological factors in patients admitted to the intensive care unit (ICU) with sepsis. METHODS: In this double-blind clinical trial, 90 ICU sepsis patients with GCS lower than 13 were randomized to receive either an intervention tablet containing 100 mg of saffron or a placebo tablet containing 100 mg of corn starch for seven days. Before and after the intervention, clinical, inflammatory, hematological, and mortality parameters were assessed. RESULTS: After seven days, the saffron group showed a significantly decline from baseline compared to the placebo group in inflammatory markers, including CRP (-24.58 ± 22.16 vs. -2.42 ± 30.86; P < 0.001), ESR (-5.36 ± 28.75 vs. 24.29 ± 28.24; P < 0.001), IL-6 (-22.09 ± 25.22 vs. -4.02 ± 20.04; P < 0.001), IL-18 (-9.56 ± 9.31 vs. -0.89 ± 3.38; P < 0.001), and TNF-α (-2.52 ± 3.79 vs. -0.035 ± 2.35; P < 0.001). Regarding clinical outcomes, significant improvements were observed in APACHE II (-2.55 ± 5.47 vs. 0.78 ± 3.37; P = 0.003), SOFA (-1 ± 1.07 vs. -0.05 ± 1.53; P < 0.001), NUTRIC score (-1.2 ± 1.01 vs. 0.2 ± 0.87; P < 0.001), and WBC count (-4176.34 ± 4063.01 vs. 61.57 ± 4118.97; P < 0.001). Moreover, the effect sizes (Cohen's d) for these factors ranged from moderate to large, except for IL-6, which had a small effect size (d = -0.38). However, no significant differences were found between the groups in the Glasgow Coma Scale, FOUR Score, 28-day and 90-day mortality rates, or other hematological parameters (P > 0.05). CONCLUSIONS: Saffron administration in sepsis patients admitted to the ICU led to significant improvements in inflammatory markers and some clinical parameters. However, the clinical significance of these findings remains to be fully established. TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT20201129049534N8. It was registered on 17 March 2024.